Academic Qualification
Institution [ Date from – to ] |
Degree(s) or Diploma(s) obtained: |
St. Jude Children’s Research Hospital, Memphis ‘IN. USA 2003 |
Postdoctoral Fellow |
East Carolina University, Greenville North Carolina, USA, 2002 |
Ph.D. Medical Physiology |
Dartmouth College Hanover, NH, USA. 1998 |
Special graduate program for Ph.D. |
Moi University (Maseno College), Maseno, Kenya 1997 |
M. Phil. (Not yet awarded), Molecular Biology |
B.S., Kenyatta University, Nairobi, Kenya. 1991 |
B.Sc. Botany and Zoology |
Field of Specialization
| Professor of Medical Physiology, Lung inflammatory Diseases |
Membership of Professional Bodies
- American Physiological Society
- Association of African Biomedical Scientists
|
Work Experience
- 2017-To date – Registrar Planning. Partnership, Research and Innovation, Kibabii University, Kenya
- 2017-2018 – Professor of Medical Physiology, Uzima College of Medicine, Kenya
- 2013-2017 – Cabinet Minister for Water, Energy and Natural Resources, Kisumu County Government, Kenya
- 2013-2017 – Director, Kisumu Water and Sewerage Company (KIWASCO)
- 2009-2012 – Associate Professor of Pharmacology, Florida A and M University College of Pharmacy and Pharmaceutical Sciences, Florida, USA
- 2008- 2009 -Assistant Professor of Pharmacology, Florida A&M University College of Pharmacy, Tallahassee, Florida, USA.
- 2005 – 2008 – Assistant Professor of Biology, Florida A&M University, College of Arts and Sciences, Biology Department, Tallahassee, Florida, USA
- 2005 – 2005 -Visiting Professor of Biology, Florida A&M University, College of Arts and Sciences, Biology Department, Tallahassee, Florida. USA.
- 2004 – 2005 -Research Associate, Florida A&M University College of Pharmacy, Tallahassee, Florida, USA
- 1992 – 1994 -Fisheries officer, Kenya Ministry of Tourism and Wildlife, Kenya.
- 1991 – 1992 -Biology Teacher at Riokindo High School, Kenya
|
Professional Research Interest
- The use of gene silencing for asthma therapy
- Molecular aspects of chemokine signaling and their role in cancer progression
- Identification of Eotaxins regulated genes and proteins
- Modulation of pulmonary surfactant by chemokines during lung inflammation
- Contribution of chemokines to progression of neurodegenerative inflammation
- Ce’l1 ‘specific inhibition of cancer cells proliferation
- Use of African Medicinal Plants in Cancer therapy
|
Research Experience and Funds Attracted
Grant Title |
Funding Agency |
Period/Term |
Amount (?, €, $, KES) |
Molecular mechanisms of eotaxin Secretion HD41829 (Chambers)
Role : Project Investigator
|
Faculty Research Pilot program |
2/2/06-2/2/07 |
$ 5000 |
The role of eotaxins in neurodegeneration 2G12RR03020 (Lewis)
Role : Project Investigator
|
NIH/NCRR/RCMI |
9/9/05-9/9/06 |
$ 5000 |
“airway Epithelial cells as targets for Anti- inflammatory Respirable Antisense Oligonucleotides”
G12RR03020
Role : Collaborating with Dr. Heiman
|
NIH/RCMI |
08/13/03 -05/31/2008 |
$ 502,722 |
Targeted knockdown of CTP as a mechanism for killing lung tumor cells
2G12RR03020 (Lewis)
Role : Project Investigator
|
NIH/NCRR/RCMI |
9/9/07-9/9/08 |
$ 5000 |
Small interfering RNA targeting Airway chemokines
GM-008111
Role : Collaborating with Dr. Heiman
|
NIH/NIGMS/MBRS |
5/1/06-4/30/09 |
$500,000 |
Identification of eotaxin-3-regulated genes and proteins in alveolar type II cell”
IR15HL093710-01A1
Role : Principal Investigator
|
NIH |
06/01/2009-06/01/2011 |
$212,550 |
“Identification of cytokines and chemokines associated with parkinson’s disease”
G12RR03020 (Lewis)
Soliman, Core Director
Role : Project Investigator
|
NIH/NCRR/RCMI |
09/09/08-06/30/2013 |
$10,500 |
“Biotechnology pathways to Disease prevention and Therapy”
G12RR03020 (Lewis) 09/09/08- Goodman, Core Director
Role: Faculty Coordinator
|
NIH/NCRR/RCMI |
06/30/2013 |
$1,533,541 |
CC chemokines and neurodegenaration G12RR03020 (Lewis) 09/09/08- Goodman, Core Director
Role: Project Investigator
|
NIH/NCRR/RCMI |
09/30/2009 |
$6,000 |
Air Force research lab/RV Eglin AFB.
“The DREAM summer program for recruitment of minorities into the STEM disciplines”
Role: Sub Contractor
|
DOD |
04/05/2010-04/05/2011 |
$10,000 |
The Role of Novel Substituted Diindolylmethane Analogues in the treatment of triple- Negative and ErbB2- positive Breast Cancer.
Role: Project Investigator
|
Department of Defence (DOD)- Army Breast cancer research program (BCRP) |
04/05/2011-04/05/2014 |
$1,400,000 |
Consultancy
Books and Book Chapters
Selected Publications 2015-2018: Books and Book Chapters
- Lamango N. S, Koikov L Randolf D., Abonyo KO and Hubbard J. (2007). Non¬cholinergic organophospphorous toxicity: possible mechanisms involving protein prenylation pathway. A chapter in a book entitled Neurotoxicity syndromes, Nova Publishers. ISBN: 1-60021-797-4.
- B.O. Abonyo and R Marijani (2010). Efforts to eradicate asthma. International Innovation, June 2010, pg. 71-73.
- Abonyo, B., Cornell, E., Fixman, 1, Rittman, J. and Wallace, D. (1998) Lake Victoria, A mathematical Ecohistory. (The book is currently in use in Dartmouth college Math curriculum at www.math.dartmouth.edwmatc/math5.medicalllake vict.pdf
|
Scientific Articles Published
Selected Publications 2015-2018: Scientific Articles Published in Refereed Journals
- Rukia Marijani, Tierre Matthews, Hasina McGann, Nazarius Lamango, and Barack 0. Abonyo (2011). Regulatory effect of ccl26 on cancer related genes. The FASEB Journal. 25:561.7
- Marijani R. and Abonyo B.O. (2011). CTP: Phosphocholine cytidyltransferase alpha (CCT?) siRNA induce cell death of lung cancer cells. Pharm Anal Acta 2:121. doi:l0.417212153-2435.1000121
- Errahali J. Younes, Taka Equar, Abonyo BO. and Heiman A.S. (2009). CCL26- targeted siRNA treatment of alveolar type II cells decreases expression of CCR3 binding chemokines and reduces eosinophil migration: Implications in asthma therapy. Journal of Interferon and Cytokine Research .29(4): 227-240
- Equar Taka, Younes J. Errahali, Barack O. Abonyo, David M. Bauer and Ann S. Heiman * (2008). Post-transcriptional silencing of CCR3 downregulates 1L-4 stimulated release of eotaxin-3 (CCL26) and other CCR3 ligands in alveolar type II cells. Cytokine.44 (3):342-51.
- Lamango N. S, Koikov L Randolf D., Abonyo KO and Hubbard J. (2007). Noncholinergic organophospphorous toxicity: possible mechanisms involving protein prenylation pathway. A chapter in a book entitled Neurotoxicity syndromes, Nova Publishers. ISBN: 1-60021-797-4.
- Abonyo BO, Lebby K. D, Tonry, J. H, Ahmad, M, Heiman, A S. (2006). Modulation of eotaxin-3 (CCL26) in alveolar type II epithelial cells. Cytokine. 36:237-44.
- Abonyo BO, Alexander MS and Heiman AS. (2005). Autoregulation of CCL26 synthesis and secretion in A549 cells: A possible mechanism by which alveolar epithelial cells modulate airway inflammation. Am. J. Physiol. Lung Cell Mol Physiol, 289:lA78-88.
- Heiman, A, Abonyo, B., Darling-Reed, S. and Alexander, M. (2005). Cyt.okine stimulated human lung alveolar epithelial cells release eotaxin-2 (CCL24) and eotaxin-3 (CCL26). J. Interferon and Cytokine Res 25:82-91. (Picture developed in our laboratory was used for the cover of this journal).
|
